Story’s next chapter begins
Revenio’s investor story remains interesting, as the strategy’s next phase begins after the acquisition of CenterVue. The core business continues to grow very profitably, the underlying market has strong structural growth drivers, and the products have exceptionally strong competitive advantages. Revenio has also shown over the years how capable they are in value creation through investments into product development, structural transitions, and long-term growth development projects.
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
Read more on company pageKey Estimate Figures2019-10-01
| 2018 | 19e | 20e | |
|---|---|---|---|
| Revenue | 30.7 | 50.1 | 67.0 |
| growth-% | 14.6 % | 63.4 % | 33.8 % |
| EBIT (adj.) | 10.2 | 14.3 | 21.2 |
| EBIT-% (adj.) | 33.3 % | 28.5 % | 31.6 % |
| EPS (adj.) | 0.34 | 0.47 | 0.63 |
| Dividend | 0.28 | 0.34 | 0.44 |
| Dividend % | 2.2 % | 2.7 % | 3.5 % |
| P/E (adj.) | 36.9 | 26.7 | 20.1 |
| EV/EBITDA | 27.1 | 29.1 | 15.1 |
Forum discussions
